BioVie(NASDAQ:BIVI): Advancing Transformative Therapies for Neurodegeneration and Liver Disease
6 months ago
1
BioVie is a clinical-stage company developing what it believes will be transformative therapies to overcome unmet medical needs in neurodegeneration and liver disease. The Company is developing NE3107 for Alzheimer’s (AD) and Parkinson’s (PD) and BIV201 for refractory ascites. BioVie is poised for significant catalysts in 2023, including data read out from its Alzheimer’s Phase 3 trial, expected in Q4 2023, as well as interim data read outs from the Company’s planned Phase 3 study in Parkinson’s. BioVie has multiple other efforts underway that may create additional catalysts and will be announced publicly when the Company deems appropriate. https://bit.ly/BioVie
Loading comments...
-
0:21
RedChip
10 months agoBioVie: Developing Breakthrough Therapies for Unmet Medical Needs
6 -
8:05
RedChip
8 months agoIn the Spotlight: BioVie's (NASDAQ: BIVI) Quest to Tackle Alzheimer's, Parkinson's, and More
2 -
2:55
NewsUpdate
1 year agoNew treatment hailed as major breakthrough in fighting Alzheimer’s
45 -
2:59
WSYM
4 years agoBiohaven Pharmaceuticals - 2/5/20
13 -
1:16
Top Usa NEWS FEEDER
1 year agoFDA Approves New Drug for Early Treatment of Alzheimer’s
27 -
3:03
WMAR
11 months agoClinical trial results released for potential new Alzheimer's drug
5 -
11:36
Debatables
1 year agoThe FDA and BioGen did NOT want you to know THIS about their latest Alzheimer drug collusion. Ep. 13
5 -
13:44
Peak Human Labs
1 year agoNew Breakthrough Alzheimer's Drug Approved!
32 -
2:43
Just the News
1 year agoFDA considers gene therapy to treat rare muscle disease
1.86K1 -
1:20
Cryptostreets
1 month agoNew Target for Treating Degenerative Diseases Like Alzheimer’s and Parkinson’s
13